Fresenius Medical Care AG & Co. KGAA (FME) Given a €95.60 Price Target at J P Morgan Chase & Co

Fresenius Medical Care AG & Co. KGAA (ETR:FME) received a €95.60 ($113.81) target price from J P Morgan Chase & Co in a note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the stock. J P Morgan Chase & Co’s target price would indicate a potential upside of 11.96% from the company’s previous close.

Several other equities research analysts have also recently weighed in on FME. Deutsche Bank set a €84.00 ($100.00) price target on shares of Fresenius Medical Care AG & Co. KGAA and gave the stock a “neutral” rating in a research report on Tuesday, August 8th. Goldman Sachs Group set a €97.00 ($115.48) price target on shares of Fresenius Medical Care AG & Co. KGAA and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Commerzbank set a €88.00 ($104.76) price target on shares of Fresenius Medical Care AG & Co. KGAA and gave the stock a “neutral” rating in a research report on Monday, August 7th. Berenberg Bank set a €92.10 ($109.64) price objective on shares of Fresenius Medical Care AG & Co. KGAA and gave the company a “buy” rating in a research report on Monday, August 7th. Finally, Citigroup set a €92.00 ($109.52) price objective on shares of Fresenius Medical Care AG & Co. KGAA and gave the company a “buy” rating in a research report on Tuesday, August 8th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of €89.06 ($106.03).

Shares of Fresenius Medical Care AG & Co. KGAA (FME) opened at €85.39 ($101.65) on Tuesday. Fresenius Medical Care AG & Co. KGAA has a 1 year low of €71.49 ($85.11) and a 1 year high of €89.22 ($106.21).

ILLEGAL ACTIVITY WARNING: This piece was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.com-unik.info/2017/12/05/fresenius-medical-care-ag-95-60-price-target-at-j-p-morgan-chase-co.html.

Fresenius Medical Care AG & Co. KGAA Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.

Analyst Recommendations for Fresenius Medical Care AG & Co. KGAA (ETR:FME)

What are top analysts saying about Fresenius Medical Care AG & Co. KGAA? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fresenius Medical Care AG & Co. KGAA and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit